Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. SYRS Peers
See (SYRS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYRS | $0.03 | +200.00% | 241.5K | N/A | -$3.07 | N/A |
| VRTX | $470.53 | -1.76% | 123.2B | -125.89 | -$3.81 | N/A |
| REGN | $563.74 | +2.02% | 59.4B | 14.22 | $39.36 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $317.29 | -1.11% | 42.1B | -153.69 | -$2.10 | N/A |
| ARGX | $563.10 | +1.43% | 34.4B | 34.37 | $16.39 | N/A |
| BNTX | $112.65 | +0.77% | 27.4B | -30.31 | -$3.76 | N/A |
| RPRX | $35.87 | +0.00% | 20.3B | 14.74 | $2.45 | +2.95% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.09 | +1.39% | 19.2B | -76.19 | -$0.34 | N/A |
Stock Comparison
SYRS vs VRTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, SYRS is priced at $0.03, while VRTX trades at $470.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -125.89. In terms of profitability, SYRS's ROE is -27.47%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SYRS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs REGN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, REGN has a market cap of 59.4B. Regarding current trading prices, SYRS is priced at $0.03, while REGN trades at $563.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 14.22. In terms of profitability, SYRS's ROE is -27.47%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SYRS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs SGEN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SYRS is priced at $0.03, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SYRS's ROE is -27.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SYRS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ALNY Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ALNY has a market cap of 42.1B. Regarding current trading prices, SYRS is priced at $0.03, while ALNY trades at $317.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -153.69. In terms of profitability, SYRS's ROE is -27.47%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SYRS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ARGX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ARGX has a market cap of 34.4B. Regarding current trading prices, SYRS is priced at $0.03, while ARGX trades at $563.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 34.37. In terms of profitability, SYRS's ROE is -27.47%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, SYRS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BNTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BNTX has a market cap of 27.4B. Regarding current trading prices, SYRS is priced at $0.03, while BNTX trades at $112.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -30.31. In terms of profitability, SYRS's ROE is -27.47%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SYRS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RPRX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, SYRS is priced at $0.03, while RPRX trades at $35.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 14.74. In terms of profitability, SYRS's ROE is -27.47%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SYRS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BGNE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SYRS is priced at $0.03, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SYRS's ROE is -27.47%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SYRS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs SMMT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, SMMT has a market cap of 19.2B. Regarding current trading prices, SYRS is priced at $0.03, while SMMT trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -76.19. In terms of profitability, SYRS's ROE is -27.47%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SYRS is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs DNA-WT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SYRS is priced at $0.03, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SYRS's ROE is -27.47%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SYRS is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs INCY Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, SYRS is priced at $0.03, while INCY trades at $69.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 351.65. In terms of profitability, SYRS's ROE is -27.47%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SYRS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs UTHR Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, UTHR has a market cap of 13.5B. Regarding current trading prices, SYRS is priced at $0.03, while UTHR trades at $297.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 11.96. In terms of profitability, SYRS's ROE is -27.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SYRS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs GMAB Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, SYRS is priced at $0.03, while GMAB trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 12.86. In terms of profitability, SYRS's ROE is -27.47%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SYRS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MRNA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MRNA has a market cap of 13.3B. Regarding current trading prices, SYRS is priced at $0.03, while MRNA trades at $33.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.93. In terms of profitability, SYRS's ROE is -27.47%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SYRS is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs KRTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SYRS is priced at $0.03, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SYRS's ROE is -27.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SYRS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs EXEL Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, EXEL has a market cap of 12.3B. Regarding current trading prices, SYRS is priced at $0.03, while EXEL trades at $45.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 20.62. In terms of profitability, SYRS's ROE is -27.47%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SYRS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BMRN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, SYRS is priced at $0.03, while BMRN trades at $58.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 21.79. In terms of profitability, SYRS's ROE is -27.47%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SYRS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ASND Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ASND has a market cap of 10.6B. Regarding current trading prices, SYRS is priced at $0.03, while ASND trades at $175.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -25.79. In terms of profitability, SYRS's ROE is -27.47%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SYRS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RXDX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SYRS is priced at $0.03, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SYRS's ROE is -27.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SYRS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs VRNA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, SYRS is priced at $0.03, while VRNA trades at $104.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -52.42. In terms of profitability, SYRS's ROE is -27.47%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SYRS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BBIO Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, SYRS is priced at $0.03, while BBIO trades at $46.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -13.00. In terms of profitability, SYRS's ROE is -27.47%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SYRS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs IMGN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SYRS is priced at $0.03, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SYRS's ROE is -27.47%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, SYRS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs TECH Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, SYRS is priced at $0.03, while TECH trades at $53.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 65.55. In terms of profitability, SYRS's ROE is -27.47%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SYRS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BPMC Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SYRS is priced at $0.03, while BPMC trades at $129.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.73. In terms of profitability, SYRS's ROE is -27.47%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SYRS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CERE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SYRS is priced at $0.03, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, SYRS's ROE is -27.47%, compared to CERE's ROE of -0.43%. Regarding short-term risk, SYRS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ROIV Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, SYRS is priced at $0.03, while ROIV trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -15.42. In terms of profitability, SYRS's ROE is -27.47%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, SYRS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ROIVW Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, SYRS is priced at $0.03, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SYRS's ROE is -27.47%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, SYRS is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CORT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, SYRS is priced at $0.03, while CORT trades at $71.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 62.67. In terms of profitability, SYRS's ROE is -27.47%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SYRS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RVMD Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, SYRS is priced at $0.03, while RVMD trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -9.60. In terms of profitability, SYRS's ROE is -27.47%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SYRS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs AMRN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, AMRN has a market cap of 7.1B. Regarding current trading prices, SYRS is priced at $0.03, while AMRN trades at $17.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -3.92. In terms of profitability, SYRS's ROE is -27.47%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, SYRS is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs HALO Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, SYRS is priced at $0.03, while HALO trades at $57.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 15.33. In terms of profitability, SYRS's ROE is -27.47%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SYRS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MDGL Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MDGL has a market cap of 7B. Regarding current trading prices, SYRS is priced at $0.03, while MDGL trades at $315.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -17.65. In terms of profitability, SYRS's ROE is -27.47%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SYRS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs JAZZ Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, SYRS is priced at $0.03, while JAZZ trades at $110.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 15.28. In terms of profitability, SYRS's ROE is -27.47%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SYRS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs IONS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, SYRS is priced at $0.03, while IONS trades at $41.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -14.18. In terms of profitability, SYRS's ROE is -27.47%, compared to IONS's ROE of -0.92%. Regarding short-term risk, SYRS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RETA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SYRS is priced at $0.03, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, SYRS's ROE is -27.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SYRS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs TGTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, SYRS is priced at $0.03, while TGTX trades at $37.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 150.68. In terms of profitability, SYRS's ROE is -27.47%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SYRS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RYTM Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, SYRS is priced at $0.03, while RYTM trades at $87.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -31.82. In terms of profitability, SYRS's ROE is -27.47%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SYRS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ABCM Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SYRS is priced at $0.03, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SYRS's ROE is -27.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SYRS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ISEE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SYRS is priced at $0.03, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SYRS's ROE is -27.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SYRS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs AXSM Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, SYRS is priced at $0.03, while AXSM trades at $109.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -18.82. In terms of profitability, SYRS's ROE is -27.47%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SYRS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs NUVL Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, SYRS is priced at $0.03, while NUVL trades at $81.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.57. In terms of profitability, SYRS's ROE is -27.47%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SYRS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs TLX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, SYRS is priced at $0.03, while TLX trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 178.44. In terms of profitability, SYRS's ROE is -27.47%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SYRS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CRSP Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, SYRS is priced at $0.03, while CRSP trades at $56.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -13.14. In terms of profitability, SYRS's ROE is -27.47%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SYRS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ALKS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, SYRS is priced at $0.03, while ALKS trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 14.51. In terms of profitability, SYRS's ROE is -27.47%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SYRS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs PCVX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, SYRS is priced at $0.03, while PCVX trades at $35.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -9.09. In terms of profitability, SYRS's ROE is -27.47%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SYRS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ALPN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SYRS is priced at $0.03, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SYRS's ROE is -27.47%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, SYRS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ADMA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, SYRS is priced at $0.03, while ADMA trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 21.99. In terms of profitability, SYRS's ROE is -27.47%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SYRS is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CYTK Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, SYRS is priced at $0.03, while CYTK trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.91. In terms of profitability, SYRS's ROE is -27.47%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SYRS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs KRYS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, SYRS is priced at $0.03, while KRYS trades at $147.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 36.03. In terms of profitability, SYRS's ROE is -27.47%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SYRS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs OPT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SYRS is priced at $0.03, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, SYRS's ROE is -27.47%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SYRS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs AKRO Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, SYRS is priced at $0.03, while AKRO trades at $51.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -13.86. In terms of profitability, SYRS's ROE is -27.47%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SYRS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MRTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SYRS is priced at $0.03, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SYRS's ROE is -27.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SYRS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MRUS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MRUS has a market cap of 4.1B. Regarding current trading prices, SYRS is priced at $0.03, while MRUS trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -13.25. In terms of profitability, SYRS's ROE is -27.47%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SYRS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs SLNO Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, SLNO has a market cap of 4B. Regarding current trading prices, SYRS is priced at $0.03, while SLNO trades at $82.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -16.94. In terms of profitability, SYRS's ROE is -27.47%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SYRS is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs PTCT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, SYRS is priced at $0.03, while PTCT trades at $48.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.61. In terms of profitability, SYRS's ROE is -27.47%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SYRS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MTSR Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MTSR has a market cap of 3.8B. Regarding current trading prices, SYRS is priced at $0.03, while MTSR trades at $38.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -14.34. In terms of profitability, SYRS's ROE is -27.47%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, SYRS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ACLX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, SYRS is priced at $0.03, while ACLX trades at $68.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -23.05. In terms of profitability, SYRS's ROE is -27.47%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SYRS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RNA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RNA has a market cap of 3.8B. Regarding current trading prices, SYRS is priced at $0.03, while RNA trades at $31.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -10.49. In terms of profitability, SYRS's ROE is -27.47%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SYRS is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ZLAB Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, SYRS is priced at $0.03, while ZLAB trades at $32.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -13.62. In terms of profitability, SYRS's ROE is -27.47%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, SYRS is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RYZB Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SYRS is priced at $0.03, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SYRS's ROE is -27.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SYRS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CBAY Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SYRS is priced at $0.03, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SYRS's ROE is -27.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SYRS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ACAD Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, SYRS is priced at $0.03, while ACAD trades at $21.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 16.10. In terms of profitability, SYRS's ROE is -27.47%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SYRS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs LEGN Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, LEGN has a market cap of 3.7B. Regarding current trading prices, SYRS is priced at $0.03, while LEGN trades at $39.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -33.66. In terms of profitability, SYRS's ROE is -27.47%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SYRS is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs SRRK Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, SRRK has a market cap of 3.6B. Regarding current trading prices, SYRS is priced at $0.03, while SRRK trades at $37.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.95. In terms of profitability, SYRS's ROE is -27.47%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SYRS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs AAPG Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, SYRS is priced at $0.03, while AAPG trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -54.43. In terms of profitability, SYRS's ROE is -27.47%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SYRS is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs SWTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SYRS is priced at $0.03, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SYRS's ROE is -27.47%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SYRS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs VKTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, SYRS is priced at $0.03, while VKTX trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -26.97. In terms of profitability, SYRS's ROE is -27.47%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SYRS is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs PTGX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, SYRS is priced at $0.03, while PTGX trades at $53.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 67.77. In terms of profitability, SYRS's ROE is -27.47%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SYRS is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs KYMR Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, SYRS is priced at $0.03, while KYMR trades at $44.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -14.52. In terms of profitability, SYRS's ROE is -27.47%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SYRS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MLTX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MLTX has a market cap of 3.1B. Regarding current trading prices, SYRS is priced at $0.03, while MLTX trades at $49.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -21.29. In terms of profitability, SYRS's ROE is -27.47%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, SYRS is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CRNX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, SYRS is priced at $0.03, while CRNX trades at $31.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -8.42. In terms of profitability, SYRS's ROE is -27.47%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SYRS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs IMVT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, IMVT has a market cap of 3B. Regarding current trading prices, SYRS is priced at $0.03, while IMVT trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -6.41. In terms of profitability, SYRS's ROE is -27.47%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, SYRS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RARE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, SYRS is priced at $0.03, while RARE trades at $29.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -5.32. In terms of profitability, SYRS's ROE is -27.47%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SYRS is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs NAMSW Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, NAMSW has a market cap of 2.9B. Regarding current trading prices, SYRS is priced at $0.03, while NAMSW trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SYRS's ROE is -27.47%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, SYRS is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MORF Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SYRS is priced at $0.03, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, SYRS's ROE is -27.47%, compared to MORF's ROE of -0.22%. Regarding short-term risk, SYRS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MOR Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SYRS is priced at $0.03, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, SYRS's ROE is -27.47%, compared to MOR's ROE of -1.84%. Regarding short-term risk, SYRS is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs KDNY Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, SYRS is priced at $0.03, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SYRS's ROE is -27.47%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SYRS is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CPRX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, SYRS is priced at $0.03, while CPRX trades at $21.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 13.91. In terms of profitability, SYRS's ROE is -27.47%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SYRS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MYOV Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, SYRS is priced at $0.03, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SYRS's ROE is -27.47%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SYRS is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs MIRM Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, SYRS is priced at $0.03, while MIRM trades at $53.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -32.90. In terms of profitability, SYRS's ROE is -27.47%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SYRS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs ARWR Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, ARWR has a market cap of 2.6B. Regarding current trading prices, SYRS is priced at $0.03, while ARWR trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -15.22. In terms of profitability, SYRS's ROE is -27.47%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, SYRS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs IBRX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, SYRS is priced at $0.03, while IBRX trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -5.05. In terms of profitability, SYRS's ROE is -27.47%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SYRS is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs XENE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, SYRS is priced at $0.03, while XENE trades at $32.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -10.24. In terms of profitability, SYRS's ROE is -27.47%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SYRS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs NAMS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, SYRS is priced at $0.03, while NAMS trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -11.96. In terms of profitability, SYRS's ROE is -27.47%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, SYRS is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs APLS Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, SYRS is priced at $0.03, while APLS trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -10.84. In terms of profitability, SYRS's ROE is -27.47%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SYRS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs LGND Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, LGND has a market cap of 2.4B. Regarding current trading prices, SYRS is priced at $0.03, while LGND trades at $121.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -17.14. In terms of profitability, SYRS's ROE is -27.47%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SYRS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs PRVB Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, SYRS is priced at $0.03, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SYRS's ROE is -27.47%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SYRS is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs LBPH Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, SYRS is priced at $0.03, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SYRS's ROE is -27.47%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SYRS is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs APGE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, SYRS is priced at $0.03, while APGE trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -10.67. In terms of profitability, SYRS's ROE is -27.47%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SYRS is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs AGIO Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, SYRS is priced at $0.03, while AGIO trades at $39.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 3.43. In terms of profitability, SYRS's ROE is -27.47%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, SYRS is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs RXRX Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, SYRS is priced at $0.03, while RXRX trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas RXRX's P/E ratio is -3.40. In terms of profitability, SYRS's ROE is -27.47%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, SYRS is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs DICE Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, SYRS is priced at $0.03, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, SYRS's ROE is -27.47%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SYRS is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs DNLI Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, SYRS is priced at $0.03, while DNLI trades at $14.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.75. In terms of profitability, SYRS's ROE is -27.47%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SYRS is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs BEAM Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, SYRS is priced at $0.03, while BEAM trades at $21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas BEAM's P/E ratio is -4.78. In terms of profitability, SYRS's ROE is -27.47%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, SYRS is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs VCYT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, SYRS is priced at $0.03, while VCYT trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 65.52. In terms of profitability, SYRS's ROE is -27.47%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SYRS is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CALT Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, SYRS is priced at $0.03, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, SYRS's ROE is -27.47%, compared to CALT's ROE of -1.67%. Regarding short-term risk, SYRS is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs KNSA Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, SYRS is priced at $0.03, while KNSA trades at $28.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -120.58. In terms of profitability, SYRS's ROE is -27.47%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SYRS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs VCEL Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, SYRS is priced at $0.03, while VCEL trades at $40.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 824.80. In terms of profitability, SYRS's ROE is -27.47%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SYRS is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.
SYRS vs CGON Comparison
SYRS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRS stands at 241.5K. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, SYRS is priced at $0.03, while CGON trades at $26.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRS currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -18.30. In terms of profitability, SYRS's ROE is -27.47%, compared to CGON's ROE of -0.17%. Regarding short-term risk, SYRS is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SYRS.